← 홈

다발성 골수종

259개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 259개
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Selinexor, dexamethasone, ixazomib, pomalidomide (Selinexor, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 ACTIVE
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Venetoclax, dexamethasone, ixazomib, pomalidomide (Venetoclax, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 ACTIVE
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, 89Zr-DFO-daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
임상시험 2상태 DISCONTINUED
ADCBiologicstaleAbbViePhase 1

ABBV-838 (ABBV-838)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 2상태 DISCONTINUED
CGTBiologicstaleAnhui Provincial HospitalPreclinical

Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis. (Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis.)

Immune Thrombocytopenia (ITP) · CD19

#CD19#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 2상태 RECRUITING
CGTBiologicstaleYake Biotechnology Ltd.Phase 1

Assigned Interventions CD19/BCMA CAR T-cells (Assigned Interventions CD19/BCMA CAR T-cells)

Scleroderma; Autoimmune Diseases · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 2상태 ACTIVE
CGTBiologicstaleYake Biotechnology Ltd.Phase 2

BCMA CAR-T cells (BCMA CAR-T cells)

Multiple Myeloma; New Diagnosis Tumor · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 2상태 ACTIVE
CGTBiologicstaleBioray LaboratoriesPhase 2

BCMA-CART (BCMA-CART)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 2상태 DISCONTINUED
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab Mafodotin, Cyclophosphamide and Dexamethasone)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 3%임상시험 2상태 DISCONTINUED
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin frozen liquid)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 34%임상시험 2상태 ACTIVE
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin, Venetoclax)

Multiple Myeloma; Multiple Myeloma in Relapse · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 RECRUITING
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 ACTIVE
CGTBiologicstaleEssen BiotechPhase 2

CD19/BCMA CAR T-cells (CD19/BCMA CAR T-cells)

Systemic Lupus Erythematosus; Lupus Nephritis · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 2상태 RECRUITING
CGTBiologicstaleCartesian TherapeuticsPhase 2

Descartes-08 (Descartes-08)

Multiple Myeloma · Antisynthetase Syndrome

#AntisynthetaseSyndrome#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 2상태 RECRUITING
AntibodystalePfizerPhase 2

Elranatamab-bcmm (Elranatamab-bcmm)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
임상시험 2상태 RECRUITING
CGTBiologicstaleJuno Therapeutics, a Subsidiary…Phase 2

JCARH125 (JCARH125)

Non Hodgkin Lymphoma; Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 42.9%임상시험 2상태 ACTIVE
AntibodystaleTakedaPhase 2

Mezagitamab (Mezagitamab)

Relapsed and/or Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 25%임상시험 2상태 ACTIVE
CGTBiologicstaleOriCell Therapeutics Co., Ltd.Phase 2

OriCAR-017 (OriCAR-017)

Relapsed and/or Refractory Multiple Myeloma · Neoplasms, Plasma Cell

#NeoplasmsPlasmaCell#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 2상태 RECRUITING
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, 89Zr-daratumumab PET/CT)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
CGTBiologicstaleAutolus LimitedPhase 2

AUTO CAR T cell therapy (AUTO CAR T cell therapy)

Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy; Multiple Myeloma · Patients Followed for up to 15 Years Fol

#PatientsFollowedforupto15YearsFo#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE

5 / 13 페이지

← 이전다음 →